×
戻る Agenda
Session 1: Keynote Address
Session Chair(s)
Representative Invited
United States
Session 1: Keynote Address
Learning Objective : At the conclusion of this session, participants should be able to: - Mention key themes in the draft ICH S13 guideline on nonclinical safety for oligos
- Discuss specific situations where a NAMs approach could be applied to an oligo project
- Suggest potential areas in the oligo project Drug Discovery and Development value chain where application AI could add significant value
Speaker(s)
Paul Hakan Anderson
, AstraZeneca, Sweden
Session 8: Hot Topics